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Objectives The purpose of this study was to assess atrial myocardial perfusion in patients with lone recurrent atrial fibrilla-
tion (LRAF).
Background Although acute atrial ischemia has been implicated in the pathogenesis of atrial fibrillation, there are few data
concerning human atrial myocardial perfusion and none for patients with LRAF.
Methods Sixteen patients with LRAF and 15 control subjects with suitable coronary anatomy underwent time-averaged
peak coronary blood flow velocity (APV) measurements (cm/s), using a Doppler guidewire in the proximal left
circumflex coronary artery (LCx) and in the left atrial circumflex branch (LACB), at baseline (b) and after adeno-
sine administration to achieve maximal hyperemia (h). Coronary flow reserve was defined as h-APV/b-APV.
Results Although there were no statistically significant differences in b-APV between patients with LRAF and control sub-
jects or between the LACB and LCx, there were significant group (p  0.002), artery (p  0.001), and interaction
(p  0.001) effects at maximal hyperemia. In patients with LRAF, the h-APV and coronary flow reserve of the
LACB (30.4  9.5 cm/s and 2.2  0.4, respectively) were significantly lower than in the LACB of the control sub-
jects (45.8  12.8 cm/s [p  0.001] and 2.9  0.5 [p  0.001], respectively) or in the patients’ LCx (43.0 
10.9 cm/s [p  0.001] and 3.1  0.6 [p  0.001], respectively).
Conclusions This study confirms for the first time isolated atrial myocardial perfusion abnormalities in patients with LRAF
and coronary flow reserve impairment, indicating that microvascular dysfunction is a pathophysiological sub-
strate associated with this arrhythmia. (J Am Coll Cardiol 2008;51:2053–7) © 2008 by the American College
of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.01.055o
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ctrial fibrillation (AF) is the most common arrhythmia in
linical practice and is associated with an increased long-
erm risk of stroke, heart failure, and all-cause mortality (1).
Many different factors are involved in the onset, perpet-
ation, and relapse of AF. A substantial proportion of
atients have no detectable cardiopulmonary disease, and
he underlying pathophysiological mechanisms remain ob-
cure. Nevertheless, atrial fibrosis and loss of atrial muscle
ass are the common pathoanatomic changes that have
een observed (2–5) and which may precede the onset of AF
6). Given that these anatomic changes closely resemble
hose in ventricular myocytes in the hibernating myocar-
ium (7,8), atrial ischemia has been implicated in the
athogenesis of AF.
rom the *Cardiology Department, University Hospital of Heraklion, Heraklion,
reece; and the †Biostatistics Lab, University of Crete, Heraklion, Greece.l
Manuscript received October 15, 2007; revised manuscript received January 17,
008, accepted January 21, 2008.Although there are animal studies indicating a direct effect
f acute atrial ischemia on AF pathogenesis (9), no studies have
xamined this pathophysiological relationship in humans.
The use of intracoronary Doppler has made flow velocity
easurements feasible in the atrial branches, and data
oncerning atrial myocardial perfusion have been reported
ecently from our department (10).
The purpose of the present study was to assess atrial
yocardial perfusion in patients with lone recurrent atrial
brillation (LRAF).
ethods
atients and control subjects. The study assessed 42 pa-
ients with LRAF and suitable coronary anatomy who con-
ented to undergo functional assessment of coronary circula-
ion after the completion of programmed routine cardiac
atheterization at least 1 month after the last episode of AF.
Suitable coronary anatomy means that the patients had a
eft atrial circumflex branch (LACB) at least 0.5 mm in
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Atrial CFR in Recurrent Atrial Fibrillation May 27, 2008:2053–7diameter, originating without an
obtuse angle from the left circum-
flex coronary artery (LCx). The
LACB was defined as any branch
that originated to the left of the
LCx and the coronary sinus, in the
right anterior oblique view.
Lone recurrent AF was de-
fined as 2 or more episodes of
AF over the last year without
evidence of cardiopulmonary
disease. The following patient
groups were excluded: patients
with other than sinus rhythm,
significant coronary artery dis-
ease (stenosis diameter 40%),
stenotic coronary artery lesions of
any severity of the LCx, previous
myocardial infarction, congeni-
tal, valvular, or hypertensive heart
isease, chronic obstructive pulmonary disease, thyroid dis-
ase, left atrial diameter 40 mm, and left ventricular
jection fraction 50%.
Fifteen patients without a history of AF who had coro-
ary angiography for clinical indications with coronary
rteries free of stenotic lesions and suitable coronary anat-
my constituted the control group. The same exclusion
riteria as for the LRAF patients were applied to this group.
All cardioactive medications were continued except for
ntiarrhythmics, which were discontinued at least 3 days
efore the study.
linical Characteristics foratients With LRAF and for Control Subjects
Table 1 Clinical Characteristics forPatients With LRAF and for Control Subjects
Variable
LRAF
(n  16)
Control
(n  15)
p
Value
Male/female 7/9 8/7 NS
Age (yrs) 59 8 64 8 NS
Current or ex-smokers 7 (44%) 6 (40%) NS
Hypertension 5 (31%) 4 (27%) NS
Dyslipidemia 7 (44%) 8 (53%) NS
Total cholesterol (mg/dl) 192 43 203 45 NS
Triglycerides (mg/dl) 138 47 146 41 NS
Diabetes mellitus 1 (6%) 0 (0%) NS
Beta-blockers 3 (19%) 4 (27%) NS
Calcium-channel blockers 2 (13%) 3 (20%) NS
ACE inhibitors 2 (13%) 1 (7%) NS
Statins 5 (31%) 4 (27%) NS
LA diameter/BSA (mm/m2) 19.4 2.4 18.5 2.6 NS
Number of AF episodes 3.4 1.3 —
Duration of AF history (months) 26 15 —
Time from last episode of AF (days) 74 41 —
Duration of last documented AF episode (h) 20 18 —
Abbreviations
and Acronyms
AF  atrial fibrillation
APV  time-averaged peak
coronary flow velocity
b-APV  time-averaged
peak coronary flow velocity
at baseline
CFR  coronary flow
reserve
h-APV  time-averaged
peak coronary flow velocity
after maximal hyperemia
LACB  left atrial
circumflex branch
LCx  left circumflex
coronary artery
LRAF  lone recurrent
atrial fibrillationp
CE  angiotensin-converting enzyme; AF  atrial fibrillation; BSA  body surface area; LA  left
trium; LRAF  lone recurrent atrial fibrillation; NS  not significant.All patients and control subjects gave their written
nformed consent to participation in the study. The study
rotocol was approved by the hospital’s ethics committee.
oronary flow velocity measurements. Immediately after
oronary angiography, the left coronary artery was selec-
ively engaged with a diagnostic catheter. A 0.014-inch
5-MHz Doppler guide wire (FloWire, Volcano Therapeu-
ics, Rancho Cordova, California) was advanced through
he catheter to the proximal LCx and to the LACB.
requency analysis of the Doppler signals was carried out in
eal time by fast Fourier transform using a velocimeter
FloMap, Volcano Therapeutics).
Once baseline flow-velocity data had been obtained, a
0-g bolus injection of intracoronary adenosine was given
o obtain data during hyperemia. To confirm that maximal
yperemia had been achieved, doses that were incrementally
arger by 30 g were infused until a plateau in flow velocity
as reached.
Time-averaged peak coronary flow velocity (APV) was
easured and coronary flow reserve (CFR) was determined
s the ratio of APV at maximal hyperemia (h-APV) to APV
t baseline (b-APV).
Pre-treatment and measurements were done as previously
escribed (10).
tatistical analysis. Data are expressed as mean  SD.
he 2-tailed t test for independent samples was used to
ompare continuous variables between the 2 groups.
epeated-measures analysis of variance within drug (base-
ine, adenosine-induced maximal hyperemia) and artery
LACB, LCx) factors and between groups was used to
ssess main and interaction effects on APV. The 95%
onfidence intervals (CIs) were also computed to obtain a
etter idea about the magnitude of the effects. A p value of
0.05 was considered to be statistically significant.
esults
f the 42 patients initially examined, 23 did not satisfy the
ngiographic criteria for inclusion in the study, 2 had
oppler and Other Parameters Recorded From theACB and LCx for Patients With LRAF and forntrol Subjects
Table 2
Doppler and Other Parameters Recorded From the
LACB and LCx for Patients With LRAF and for
Control Subjects
Control LRAF
LCx LACB LCx LACB
HR (beats/min) 69 11 71 12 71 13 70 14
SBP (mm Hg) 128 16 127 17 119 14 120 12
DBP (mm Hg) 70 11 69 12 67 10 68 9
b-APV (cm/s) 17.1 4.8 16.5 5.4 14.8 5.3 13.7 3.9
h-APV (cm/s) 49.9 14.7 45.8 12.8 43.0 10.9 30.4 9.5*†
CFR 3.0 0.6 2.9 0.5 3.1 0.6 2.2 0.4*†
p  0.001 compared with control subjects. †p  0.001 compared with patients’ LCx.
b-APV  time-averaged peak flow velocity at baseline; CFR  coronary flow reserve;
BP  diastolic blood pressure; h-APV  time-averaged peak flow velocity after maximal
yperemia; HR  heart rate; LACB  left atrial circumflex branch; LCx  left circumflex coronary
rtery; LRAF  lone recurrent atrial fibrillation; SBP  systolic blood pressure.oor-quality recordings, and in 1 the wire could not be
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xcluded from the final analysis.
The clinical data from the remaining 16 patients and the
ontrol subjects are given in Table 1.
eart rate and arterial blood pressure. Heart rate and
ystolic and diastolic blood pressures recorded during LCx
nd LACB Doppler measurements, in both patients and
ontrol subjects, are given in Table 2.
oronary flow velocity measurements. The Doppler pa-
ameters recorded at baseline and at maximum hyperemia
re given in Table 2.
Cx. There was a significant drug effect (p  0.001) on
PV but no significant group (p  0.14) or interaction
ffects (p  0.21) (Figs. 1 and 2).
Figure 1 Time-Averaged Peak Coronary Flow Velocity
Box-plots of time-averaged peak coronary flow velocity at baseline (b-APV) and
at maximal hyperemia (h-APV) from the left atrial circumflex branch (LACB) and
the left circumflex coronary artery (LCx) in patients with lone recurrent atrial
fibrillation (LRAF) and in control subjects.
Figure 2 CFR Recordings
Left atrial circumflex branch and LCx b-APV and h-APV from a patient with lone recurreThe CFR was 3.1  0.6 in LRAF patients and 3.0 0.6
n control subjects; the difference between these values was
ot statistically significant (p  0.72) (Fig. 3).
ACB. Although there were no significant differences in
PV between patients and control subjects at baseline, there
as a significant group effect (p  0.002) during maximal
yperemia. There were also significant drug (p 0.001) and
nteraction (p  0.001) effects. The h-APV was signifi-
antly lower in patients with LRAF than in the control
ubjects (Figs. 1 and 2).
The CFR was significantly lower in patients with LRAF
han in the control subjects (mean difference 0.62, 95% CI
.97 to 0.26; p  0.001) (Fig. 3). In patients with LRAF,
he CFR showed no significant correlation with the number
f AF episodes, the duration of AF history, the time since
he last episode of AF, or the duration of the last episode.
l fibrillation. CFR  coronary flow reserve; other abbreviations as in Figure 1.
Figure 3 CFR
Box-plots of CFR in the LACB and the LCx for patients
with LRAF and in control subjects. Abbreviations as in Figures 1 and 2.nt atria
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Atrial CFR in Recurrent Atrial Fibrillation May 27, 2008:2053–7trial branch versus LCx. In the LRAF patients, al-
hough there were no significant differences in b-APV,
here was a significant artery effect (p  0.001). There were
lso significant drug (p  0.001) and interaction (p 
.001) effects. The h-APV was significantly lower in the
ACB compared with the LCx (Figs. 1 and 2). The CFR
as significantly lower in the LACB compared with the
Cx (mean difference 0.83, 95% CI 1.16 to 0.49; p 
.001) (Fig. 3).
In the control subjects, there was a significant drug effect
p  0.001) but no significant artery (p  0.45) or interaction
p  0.40) effect. There was also no significant difference in
FR between the 2 arteries (p  0.28).
iscussion
e found that the CFR of the LACB in patients with
RAF was significantly reduced compared not only with
he LCx coronary artery but also with the corresponding
alues in the control subjects.
trial CFR in patients with LRAF. The microcirculation
s not just a network of passive channels but is also an active
ite of blood flow control. At rest (baseline), the capability
or blood flow regulation is high, because 60% of total
yocardial vascular resistance is offered by arterioles. How-
ver, when hyperemia is induced, smooth muscle vasodila-
ion results in dilatation of the arterioles and venules with
o change in the capillaries. The total myocardial vascular
esistance decreases, and the capillaries offer the most
esistance to blood flow and provide a ceiling to hyperemic
lood flow. Consequently, conditions that are associated
ith fewer capillaries are associated with reduced CFR.
Because chronic AF is associated with atrial myocardial
brosis and vascular degeneration of atrial cells (2,3), and
nterstitial and perivascular isolated atrial amyloid deposi-
ion (3) and similar pathoanatomic changes have been
bserved in patients with LRAF (4,5), functional and/or
tructural changes in the microcirculation are to be expected
nd could explain our findings of normal coronary flow at
aseline and reduced coronary flow at maximal hyperemia,
s well as the reduced CFR.
athophysiological role of coronary flow abnormalities in
RAF. Atrial myocardium is known to have unique intrin-
ic characteristics. Oxygen extraction is about one-half that
f the ventricle (11), and atrial myocytes are more sensitive
han ventricular to flow reductions (10). This peculiarity of
trial perfusion regulation, combined with the reduced
aximal blood flow found in patients with LRAF, leads to
etrimental effects on atrial blood supply. In addition, the
brillatory state in itself is a condition with high energy
equirements (11).
Consequently, these patients may exhibit repeated epi-
odes of oxygen demand/supply mismatch, atrial ischemia,
hronic atrial hypoperfusion and atrial myocardial hiberna-
ion, or even fibrosis, together with a deterioration of atrial
icrovascular dysfunction that may further aggravate coro-ary blood flow abnormalities in a vicious circle. In this
ontext of microvascular dysfunction as the pathophysiolog-
cal substrate for LRAF, we may easily explain why AF
egets AF (12).
Although it is not known whether atrial microcirculation
ysfunction in patients with LRAF has an etiologic link or
s an epiphenomenon, it may be added to the known
echanisms (13–16) that have been implicated in the
athogenesis of atrial fibrosis.
arlier studies. Recently, 2 animal studies from the same
roup not only showed that acute atrial ischemia induces a
ubstrate that supports AF maintenance (9), but also found
substrate-specific response to therapy (17). These data
urther reinforce the hypothesis that atrial ischemia contrib-
tes to the pathogenesis of AF.
tudy limitations. The limitations of intracoronary Dopp-
er in assessing myocardial perfusion have been analyzed in
previous report (10).
onclusions
his study confirms, for the first time, atrial myocardial
erfusion abnormalities and coronary flow reserve impair-
ent in patients with LRAF, indicating microvascular
ysfunction as an associated pathophysiological substrate.
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